The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. - Wikidata - wikimedia - TriplyDB

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

http://www.wikidata.org/entity/Q42826404

about

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.Regulators of homologous recombination repair as novel targets for cancer treatment.Influence of PJ34 on the genotoxicity induced by melphalan in human multiple myeloma cells.Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

P2860

Q26852274-F6E42A8C-F3E0-421B-AF97-412490D44F03 Q33603605-0210A8B0-40D6-4AF0-B692-F88216321F9E Q35200273-9DD31942-EF6C-49DB-9B20-0E8E6055DBC8 Q35582803-256D83BD-D0E8-46B4-ACDD-BF773C33B065 Q37059846-0E881939-3B59-4F53-8BF6-F1571737686C Q37372483-C4B4A9C3-FDAD-40AE-9AC7-E37699031694 Q38780396-970028DA-8742-46A9-952B-2CC0C0371F79 Q40214485-CC2EA934-4760-409D-9261-B68A9C2445A3 Q42130288-C94004DE-37F3-49B8-9420-01576DCF2B52 Q52807922-0F1E3F85-DF9C-4D2B-A626-15916F9BF3A9

P2860

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

http://www.wikidata.org/entity/Q42826404

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@en

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@nl

type

label

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@en

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@nl

prefLabel

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@en

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@nl

P1433

Q42826404-EA6AFA71-568C-4BAB-B135-5A6A1DB310ED

P1476

Q42826404-5A0F9E92-CEE0-438E-9646-7532520FFC4B

P2093

Q42826404-0E2B924B-BCD5-4B82-B373-E22C7FB26A33

Q42826404-996E8967-CC20-46D4-A93C-7C9CD6AE8107

Q42826404-B67871CB-F2DB-495F-854E-5AB16BCAF094

Q42826404-DBB1CFBA-A822-440F-9C1B-8413ECF77CD0

P2860

Q42826404-01B209E2-67DF-40CD-9F23-ABA0FB9F6A2E

Q42826404-0257E796-C936-45EE-8319-1F6DACCFD39A

Q42826404-0A634F2A-81BA-43AB-ABB8-B7188733B13C

Q42826404-1406085C-07D9-451B-BE26-15023190D644

Q42826404-16105874-3305-4ADA-823C-DAB3CF9ACD02

Q42826404-237A11BA-FF9A-4E3A-9016-CCFB0E0B95F5

Q42826404-2778360C-B09F-4824-93F3-B15F453F1850

Q42826404-30CE51E1-4729-4482-ACA9-83DFB79318AF

Q42826404-3240BE63-2100-4E88-A3E1-5460EAC1E5D2

Q42826404-47CCD073-F877-4E64-9863-088870525871

P2888

Q42826404-EC1B7385-60F9-4203-8C35-15EF8C155A24

P304

Q42826404-63F48013-6FD1-4F66-B29B-127F1F7BCF9F

P31

Q42826404-2696B164-6FA5-4FFF-9C59-ACFC44A918AF

P356

Q42826404-DCF39BA4-71D7-425E-8766-37007809BC0A

P433

Q42826404-F771005C-B26E-43EE-BA5E-0F995A04B9AD

P478

Q42826404-2BE90A97-0B8C-4732-A836-C7AA5E8FED7A

P577

Q42826404-22596BAC-10C9-487C-B9D2-F5B5CAFB99C9

P5875

Q42826404-9172D087-93FF-4B66-BD85-FB7B73FB4472

P6179

Q42826404-596A5ED2-87F4-484B-B3A3-D97517FDCFB5

P698

Q42826404-F4350B56-468A-4E7D-93AE-1894DC85DD3B

P932

Q42826404-EBD70BFF-F8BB-4E54-94EF-0B513D092809

P356

S10637-012-9886-7

P1433

Investigational New Drugs

P1476

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

@en

P2093

David Davidson

http://www.w3.org/2001/XMLSchema#string

Lawrence Panasci

http://www.w3.org/2001/XMLSchema#string

Raquel Aloyz

http://www.w3.org/2001/XMLSchema#string

Yunzhe Wang

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

PARPs and the DNA damage response

The role of PARP in DNA repair and its therapeutic exploitation

Advances in using PARP inhibitors to treat cancer

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Resistance to therapy caused by intragenic deletion in BRCA2

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer

Mechanisms of cancer drug resistance

P2888

s10637-012-9886-7

P304

461-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-012-9886-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232230856

http://www.w3.org/2001/XMLSchema#string

P6179

1007333132

http://www.w3.org/2001/XMLSchema#string

P698

23054213

http://www.w3.org/2001/XMLSchema#string

P932

3857790

http://www.w3.org/2001/XMLSchema#string